Profile data is unavailable for this security.
About the company
hVIVO plc is a United Kingdom-based specialist contract research organization (CRO). The Company is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. It provides end-to-end early clinical development services to its client base, which includes global biopharma companies. It offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. It offers additional clinical field trial services, such as patient recruitment and clinical trial site services. It runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.
- Revenue in GBP (TTM)56.04m
- Net income in GBP16.12m
- Incorporated2011
- Employees274.00
- LocationhVIVO PLC42 New RoadLONDON E1 2AXUnited KingdomGBR
- Phone+44 28 9073 7900
- Websitehttps://hvivo.com/
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
Faron Pharmaceuticals Oy | 0.00 | -26.54m |
Futura Medical PLC | 3.10m | -6.51m |
Allergy Therapeutics plc | 53.26m | -50.22m |
4Basebio PLC | 354.00k | -6.28m |
Animalcare Group Plc | 74.35m | 1.20m |
Avacta Group Plc | 16.03m | -42.08m |
Alliance Pharma plc | 170.05m | -7.06m |
hVIVO PLC | 56.04m | 16.12m |
Bioventix PLC | 13.60m | 8.67m |
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
JPMorgan Asset Management (UK) Ltd.as of 21 Mar 2024 | 35.18m | 5.17% |
Octopus Investments Ltd.as of 30 Apr 2024 | 24.01m | 3.53% |
Canaccord Genuity Wealth Ltd.as of 29 Dec 2023 | 21.68m | 3.19% |
Liontrust Investment Partners LLPas of 29 Mar 2024 | 10.37m | 1.52% |
Thornbridge Investment Management LLPas of 31 Oct 2022 | 9.97m | 1.47% |
Mandarine Gestion SAas of 30 Jun 2023 | 7.00m | 1.03% |
Janus Henderson Investors UK Ltd.as of 31 Mar 2024 | 4.11m | 0.60% |
River Global Investors LLPas of 31 Mar 2024 | 1.23m | 0.18% |
Margetts Fund Management Ltd.as of 31 Aug 2023 | 623.21k | 0.09% |
Lazard Asset Management LLCas of 31 Mar 2024 | 326.59k | 0.05% |